CN100383126C - 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 - Google Patents

作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 Download PDF

Info

Publication number
CN100383126C
CN100383126C CNB2005101253198A CN200510125319A CN100383126C CN 100383126 C CN100383126 C CN 100383126C CN B2005101253198 A CNB2005101253198 A CN B2005101253198A CN 200510125319 A CN200510125319 A CN 200510125319A CN 100383126 C CN100383126 C CN 100383126C
Authority
CN
China
Prior art keywords
compounds
carbon atoms
disease
general formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005101253198A
Other languages
English (en)
Chinese (zh)
Other versions
CN1781910A (zh
Inventor
H·威克斯卓姆
D·迪克斯特拉
B·J·文辉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1781910A publication Critical patent/CN1781910A/zh
Application granted granted Critical
Publication of CN100383126C publication Critical patent/CN100383126C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
CNB2005101253198A 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 Expired - Fee Related CN100383126C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE00014381 2000-04-18
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018082858A Division CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Publications (2)

Publication Number Publication Date
CN1781910A CN1781910A (zh) 2006-06-07
CN100383126C true CN100383126C (zh) 2008-04-23

Family

ID=20279367

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005101253198A Expired - Fee Related CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
CNB018082858A Expired - Fee Related CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018082858A Expired - Fee Related CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Country Status (19)

Country Link
US (4) US6683087B2 (cg-RX-API-DMAC7.html)
EP (1) EP1274411B1 (cg-RX-API-DMAC7.html)
JP (1) JP4819280B2 (cg-RX-API-DMAC7.html)
CN (2) CN100383126C (cg-RX-API-DMAC7.html)
AT (1) ATE300290T1 (cg-RX-API-DMAC7.html)
AU (2) AU4898201A (cg-RX-API-DMAC7.html)
CA (1) CA2406044C (cg-RX-API-DMAC7.html)
CZ (1) CZ20023455A3 (cg-RX-API-DMAC7.html)
DE (1) DE60112269T2 (cg-RX-API-DMAC7.html)
DK (1) DK1274411T3 (cg-RX-API-DMAC7.html)
ES (1) ES2244604T3 (cg-RX-API-DMAC7.html)
HU (1) HU229794B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ521860A (cg-RX-API-DMAC7.html)
PL (1) PL204661B1 (cg-RX-API-DMAC7.html)
PT (1) PT1274411E (cg-RX-API-DMAC7.html)
SE (1) SE0001438D0 (cg-RX-API-DMAC7.html)
SI (1) SI1274411T1 (cg-RX-API-DMAC7.html)
WO (1) WO2001078713A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207919B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616028A1 (en) * 2005-07-22 2007-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
US7910623B2 (en) * 2005-07-22 2011-03-22 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
MX2010009610A (es) 2008-03-17 2010-09-30 Bial Portela & Ca Sa Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
BRPI1014865B1 (pt) 2009-04-01 2020-03-17 Bial - Portela & C.A., S.A. Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica
US8492538B1 (en) * 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
WO2011034217A1 (ja) * 2009-09-18 2011-03-24 株式会社Ｒｉｖｅｒｓｏｎ ポリフェノール誘導体及びそれの産生方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
RS59666B1 (sr) 2011-12-13 2020-01-31 BIAL PORTELA & Cª S A Hemijsko jedinjenje korisno kao intermedijer za pripremu inhibitora katehol-o-metiltransferaze
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN119707810A (zh) 2019-05-21 2025-03-28 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7696829B2 (ja) 2019-05-21 2025-06-23 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
CA3249364A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NEW ESTERS OF COMPOUNDS 1, 2, 3, 4, 4A, 5, 6, 7, 8, 9, 10, 10A-DODECAHYDROBENZO [G]QUINOLIN-6-OL AND THEIR USES
AU2023259559A1 (en) 2022-04-25 2024-10-31 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565818A (en) * 1981-10-16 1986-01-21 Sandoz Ltd. Pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline derivatives
WO1991000727A1 (en) * 1989-07-05 1991-01-24 Whitby Research, Inc. Substituted 2-aminotetralins
EP0659430A1 (en) * 1993-12-21 1995-06-28 Sandoz Ltd. Use of benzo[g]quinolines in the treatment of glaucoma and for the prevention of progressive atrophy of the optic nerve
CN1236356A (zh) * 1997-08-07 1999-11-24 株式会社富吉摩托普拉泽兹 新颖的乙胺衍生物
WO2000006536A1 (en) * 1998-07-28 2000-02-10 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1179954A (fr) * 1956-02-11 1959-05-29 Rhone Poulenc Sa -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
GB1593888A (en) * 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
ZA805648B (en) * 1979-09-14 1982-04-28 Sandoz Ltd Tetraline derivatives, their production and pharmaceutical compositions containing them
EP0026848B1 (de) * 1979-09-14 1983-05-04 Sandoz Ag Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
ES2157204T3 (es) 1991-04-17 2001-08-16 Upjohn Co Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina.
DE4114325A1 (de) 1991-05-02 1992-11-05 Sandoz Ag Octahydrobenzo(g)chinolin, seine herstellung und verwendung
GB2260980A (en) * 1991-10-31 1993-05-05 Shell Int Research Preparation of unsaturated cyclic ketones
SV2001000202A (es) * 1999-10-20 2001-10-16 Warner Lambert Co Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565818A (en) * 1981-10-16 1986-01-21 Sandoz Ltd. Pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline derivatives
WO1991000727A1 (en) * 1989-07-05 1991-01-24 Whitby Research, Inc. Substituted 2-aminotetralins
EP0659430A1 (en) * 1993-12-21 1995-06-28 Sandoz Ltd. Use of benzo[g]quinolines in the treatment of glaucoma and for the prevention of progressive atrophy of the optic nerve
CN1236356A (zh) * 1997-08-07 1999-11-24 株式会社富吉摩托普拉泽兹 新颖的乙胺衍生物
WO2000006536A1 (en) * 1998-07-28 2000-02-10 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones

Also Published As

Publication number Publication date
US20030087948A1 (en) 2003-05-08
NZ521860A (en) 2004-03-26
EP1274411B1 (en) 2005-07-27
US6998405B2 (en) 2006-02-14
ES2244604T3 (es) 2005-12-16
JP4819280B2 (ja) 2011-11-24
ATE300290T1 (de) 2005-08-15
CN1234351C (zh) 2006-01-04
HU229794B1 (hu) 2014-07-28
AU4898201A (en) 2001-10-30
SI1274411T1 (sl) 2005-12-31
USRE42802E1 (en) 2011-10-04
HUP0300543A3 (en) 2009-04-28
WO2001078713A1 (en) 2001-10-25
CA2406044A1 (en) 2001-10-25
US6683087B2 (en) 2004-01-27
CZ20023455A3 (cs) 2003-04-16
PT1274411E (pt) 2005-11-30
ZA200207919B (en) 2003-10-02
CN1781910A (zh) 2006-06-07
HUP0300543A2 (hu) 2003-07-28
PL204661B1 (pl) 2010-01-29
AU2001248982B2 (en) 2005-12-15
SE0001438D0 (sv) 2000-04-18
USRE43244E1 (en) 2012-03-13
DK1274411T3 (da) 2005-11-14
CN1450894A (zh) 2003-10-22
DE60112269T2 (de) 2006-05-24
HK1088009A1 (en) 2006-10-27
US20040138281A1 (en) 2004-07-15
DE60112269D1 (de) 2005-09-01
JP2004500426A (ja) 2004-01-08
CA2406044C (en) 2009-10-27
EP1274411A1 (en) 2003-01-15
PL365113A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
CN100383126C (zh) 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
AU2001248982A1 (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
JP2521191B2 (ja) 新規フェニルエタノ―ルアミノメチルテトラリン化合物
US8278338B2 (en) Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety
EP0334538B1 (en) Therapeutically useful tetralin derivatives
US5214156A (en) Therapeutically useful tetralin derivatives
JP2665422B2 (ja) 置換された１，２，３，４−テトラヒドロシクロペント〔ｂ〕インドール、１，２，３，３ａ，４，８ａ−ヘキサヒドロシクロペント〔ｂ〕インドールおよび関連化合物
KR100213531B1 (ko) 헥사히드로아제핀 유도체, 그것들의 제법과 그것들을 함유하는 약학 조성물
EP0030526A1 (en) New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
CN101243091A (zh) 用作5－羟色胺抑制剂和5－ht1a激动剂和拮抗剂的三环化合物
HK1088009B (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US5132313A (en) Non-competitive NMDA receptor antagonists and methods for their use
NZ336122A (en) Acridin derivatives for use as analgesic that has high affinity for delta opiate receptors
US7550588B2 (en) Homotropanes with central nervous system activity
US20040162432A1 (en) Substituted octahydrophenanthrene compounds and use thereof as NMDA antagonists
JPWO1998041497A1 (ja) プロパノールアミン誘導体
CZ2001399A3 (cs) Nové 2,3,3a,4,9,9a -hexahydro-8-hydroxy-lHbenz(f)indoly, způsob jejich výroby a použití jako léčiva

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1088009

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1088009

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080423

Termination date: 20150417

EXPY Termination of patent right or utility model